GLYBERA

Pharmaceutical preparations and substances for the treatment of metabolic disorders and disorders which are a result of one or more mutations within the lipoprotein lipase gene; gene therapy vectors; biological preparations for medical use; biological preparations for medical use, namely, metabolic disorders and disorders which are a result of one or more mutations within the lipoprotein lipase gene; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders and disorders which are a result of one or more mutations within the lipoprotein lipase gene; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders and disorders which are the result of one or more mutations within the lipoprotein lipase gene; all the aforementioned goods used exclusively in the treatment of metabolic disorders and disorders which are a result of one or more mutations within the lipoprotein lipase gene

Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation